Who are Disitamab Vedotin Injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rescue medications for sacituzumab tirumotecan, Sacituzumab Govitecan (SG), DS-1062a, Dato-DXd, enfortumab vedotin (EV), Zilovertamab vedotin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/disitamab-vedotin-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Disitamab Vedotin Injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Disitamab Vedotin Injection (Disitamab Vedotin Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody-drug conjugate. Area: Oncology.

phase 2 Monoclonal antibody-drug conjugate Trop-2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Disitamab Vedotin Injection (Disitamab Vedotin Injection) — RemeGen Co., Ltd.. Disitamab vedotin is a monoclonal antibody-drug conjugate that targets the Trop-2 receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Disitamab Vedotin Injection TARGET	Disitamab Vedotin Injection	RemeGen Co., Ltd.	phase 2	Monoclonal antibody-drug conjugate	Trop-2
Rescue medications for sacituzumab tirumotecan	Rescue medications for sacituzumab tirumotecan	Merck Sharp & Dohme LLC	phase 3	antibody-drug conjugate	Trop-2
Sacituzumab Govitecan (SG)	Sacituzumab Govitecan (SG)	University of California, Irvine	phase 3	Antibody-drug conjugate (ADC)	Trop-2 (TACSTD2)
DS-1062a	DS-1062a	Gustave Roussy, Cancer Campus, Grand Paris	phase 3	Antibody-drug conjugate (ADC)	TROP-2 (Trophoblast cell surface antigen 2)
Dato-DXd	Dato-DXd	AstraZeneca	phase 3	Antibody-drug conjugate (ADC)	TROP-2 (Trophoblast cell surface antigen 2)
enfortumab vedotin (EV)	enfortumab vedotin (EV)	Astellas Pharma Global Development, Inc.	phase 3	Monoclonal antibody-drug conjugate	Nectin-4
Zilovertamab vedotin	Zilovertamab vedotin	Merck Sharp & Dohme LLC	phase 3	Monoclonal antibody-drug conjugate	CD30

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody-drug conjugate class)

GlaxoSmithKline · 2 drugs in this class
RemeGen Co., Ltd. · 2 drugs in this class
Copharos · 1 drug in this class
Eastern Cooperative Oncology Group · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Mirati Therapeutics Inc. · 1 drug in this class
NYU Langone Health · 1 drug in this class
The Lymphoma Academic Research Organisation · 1 drug in this class
Astellas Pharma Global Development, Inc. · 1 drug in this class
Yan Zhang, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Disitamab Vedotin Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/disitamab-vedotin-injection. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing